Navigation Links
Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Date:6/16/2013

h the ABC-subtype of DLBCL are difficult to treat, these results are very promising."

About Ibrutinib
Ibrutinib was designed to specifically target and selectively inhibit an enzyme called BTK. BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel — regulation of apoptosis, cell adhesion and cell migration and homing.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date 7 Phase III trials have been initiated with ibrutinib and a total of 30 ongoing trials are currently registered on http://www.clinicaltrials.gov/. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib.

About the MCL Study
111 patients with relapsed/refractory MCL were treated with ibrutinib in this Phase 2 multicenter, open-label, study at 18 sites internationally and had received a median of three prior therapies. Patients were divided into two cohorts based on prior bortezomib exposure – either bortezomib-naive (n=63) or bortezomib-exposed (n=48). Both groups received 560 mg of ibrutinib orally, once a day until disease progression or no longer tolerated by the patient. The primary endpoint of the study was ORR, with secondary endpoints being DOR, PFS, OS and frequency and severity of AEs.

When a disease is described as 'relapsed', it means that it has returned after an initial partial or total remission.[1] 'Refractory' refers to cancer that has become resistant to current treatment.[2]

About the DLBCL Study
The DLBCL study was a Phase 2 multicenter, open-label,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
2. Updated HHS Mandate Continues Attack on Religious Freedom
3. Hoggan Scientific Unveils Updated ergoFET Force Gauge for Improved Force Evaluation
4. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
5. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
6. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. New PrEP Trial Results Among Injecting Drug Users Underscore That PrEP Works When Taken Consistently
9. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
10. Lakeland Industries to Report Fiscal First Quarter Financial Results and Conduct Conference Call
11. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... SAN DIEGO, June 8, 2011 Amylin Pharmaceuticals, Inc. (NASDAQ: ... the following statement regarding the decision of the United States ... its motion for a preliminary injunction to enjoin Eli Lilly ... in anticompetitive activity and breaching its diabetes collaboration agreement with ...
... CAMBRIDGE, Mass., June 8, 2011 Regulus Therapeutics ... development of innovative medicines targeting microRNAs, and Alnylam Pharmaceuticals, ... therapeutics company, today announced the publication in ... about the antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data ...
Cached Medicine Technology:Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order 2Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order 3Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order 4Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 2Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 3Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 4Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 5Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 6Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 7
(Date:7/10/2014)... One week ahead of its annual Board meeting, ... will extend compensation benefits to workers from two months’ ... as a result of factory remediation, effective immediately. ... the closure of five factories for remediation. Structural faults ... concerns. In May, the Alliance—in a 50/50 partnership with ...
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... Redwood City, CA (PRWEB) July 10, 2014 ... Management, announced the latest results of the 4th ... the "Source-to-Pay” suite model. , Every day ... supplier data, contracts, expense forms etc. To meet ... deploying "Source-to-Pay" (S2P) suites which can be defined ...
(Date:7/10/2014)... professional football players who have shoulder stabilization surgery are ... finds. Shoulder instability is a common injury among ... to fix the problem has been unclear, the study ... who had shoulder stabilization surgery. Ninety percent of those ... as playing in at least one regular season game. ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Men who have a ... cancer, a new study suggests. But the risk ... not involved with the study said more research is ... accurate. For the study, Harvard researchers analyzed data ... for 24 years, starting in 1986. During that time, ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3
... rapidly changing the clinical practice of oncology. As scientists ... development of new tools capable of multiple, inexpensive biomarker ... essential to the success of genetically informed and personalized ... now developed a microfluidic image cytometry (MIC) platform that ...
... a single rock being overturned or an entire mountaintop ... processes, and vice versa. Ecological scientists will discuss findings ... growth to the diversity of insect species on green ... buildingsat the Ecological Society of America,s 95th Annual Meeting ...
... , , , , , ... , , AUDIO: ... School of Medicine... , Click here for more information. ... , , , , , ...
... HealthDay Reporter , MONDAY, August 2 (HealthDay News) -- ... than normal are at greater risk of developing artery-clogging ... of the arteries leading to heart disease, a new ... common assumption that modestly high cholesterol levels are nothing ...
... August 2, 2010 From the many images sent home ... viewed the plight of their country,s combat-weary veterans as stark ... But recent research at Washington State University (WSU) suggests that, ... often sets the trajectory of the balance of their lives. ...
... PICK: Boosting the efficacy of anticancer vaccines ... anticancer vaccines, which are designed to boost the patient,s ... example, the viruses used to deliver the tumor protein ... the patient,s immune system, inducing neutralizing and suppressive responses. ...
Cached Medicine News:Health News:New diagnostic chip able to generate single-cell molecular 'fingerprints' for brain tumors 2Health News:New diagnostic chip able to generate single-cell molecular 'fingerprints' for brain tumors 3Health News:Scientists unravel human-ecosystem interactions 2Health News:Scientists unravel human-ecosystem interactions 3Health News:Scientists unravel human-ecosystem interactions 4Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 2Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 3Health News:Colitis patients diagnosed later in life tend to have better disease outcomes 4Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 2Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 3Health News:High Cholesterol in Youth Boosts Heart Risk In Middle Age 4Health News:Sociologist finds combat veterans face more lifelong socioeconomic challenges 2Health News:JCI online early table of contents: August 2, 2010 2Health News:JCI online early table of contents: August 2, 2010 3Health News:JCI online early table of contents: August 2, 2010 4Health News:JCI online early table of contents: August 2, 2010 5Health News:JCI online early table of contents: August 2, 2010 6
Optimized 180W Xenon lamp, low fan noise with reduced air turbulence, compact housing. Built for monitor applications and all endoscope dimensions. Ideal for video recording applications....
High-intensity 300-watt xenon lamp, with continuously adjustable output from 0 to 100% manually or automatically by camera video output signal....
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 460 lines, NTSC output at 470 lines. 30mm focal length. 90mm length x 20mm diameter....
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 625 lines, NTSC output at 525 lines. 23mm focal length. Output via Y/C mini-DIN-4 port. 135mm length x 44mm ...
Medicine Products: